中文 / CN
Deutsch / DE
日本語 / JP
한글 / KR
Contact Us
菜单
CRO Services
Drug Development Expertise Empowering Research Services for Biologics

Early-Stage Antibody Developability Assessment

MicroDevelopability Services: High-Throughput Developability Assessment for Lead Optimization

 

Most therapeutic antibody candidates are initially screened and selected based on affinity and functionality, while other important developability factors often receive less attention. This increases unexpected risks at later stages when the candidates are narrowed down, leading to costly re-engineering or program failure. Our antibody developability assessment brings these evaluations earlier in discovery using high-throughput (HTP) assays to assess key attributes such as sequence liability, PK, biophysical properties, immunogenicity, and stability. This rapid, HTP, low-material workflow delivers clear, actionable data to support lead optimization, enable early risk assessment, and help projects progress more smoothly toward CMC development.

 

 

 

Early Developability Assessment
For lead optimization, early risk mitigation, and smooth transition to CMC
Minimal Materials Required
Low protein consumption & fast turnaround
Build Your Own Package
Expert-guided, fit-for-purpose panel for lead optimization

 

Get a Free Consultation

 

Early-stage antibody developability assessment using high-throughput assays and minimal materials to enable early risk assessment and lead optimization in drug discovery.

Our Early-Stage Antibody Developability Assessment Includes:

 

  • In silico analysis: Combines sequence-based and structural simulation for predictive risk evaluation on CDR hotspots and aggregation risks; Utilizes different algorithms and databases for immunogenicity risk evaluation
  • PK-assessment assays: Employs high-throughput assays, including self association, non-specific binding, FcRn affinity, serum stability, and thermal stability
  • Immunogenicity assays: Evaluates cytokine secretion using ELISPOT and T cell activation using FACS
  • Forced degradation studies: Enables stability assessment under stress conditions like thermal stress, freeze-thaw, and low pH, and hotspot identification under forced oxidation, deamidation, isoASP, or glycation
  • LC-MS analysis: Includes Intact MS, peptide/disulfide mapping, glycan analysis, and proteomics for in-depth protein characterization and quantification from complexed matrix

 

 

Early-stage antibody developability assessment workflow illustrating high-throughput in vitro screening assays with minimal materials, and stability evaluation to support lead optimization.

 

MicroDevelopability Service Details:

In Silico Analysis PK-Assessment Assays Immunogenicity Assays Forced Degradation Studies LC-MS Analysis
  • Sequence-based analysis
  • Structure-based analysis
  • Immunogenicity & effector function
  • Self-association / Colloidal stability
  • Non-specific binding
  • FcRn affinity
  • Serum stability
  • Thermal stability
  • ELISPOT: Cytokine secretion evaluation – IFN-γ
  • FACS-based T cell activation
  • Stability assessment under 40 °C, freeze-thaw, low pH, or agitation
  • Hotspot identification under forced oxidation, deamidation, isoAsp, or glycation
  • Intact MS
  • Peptide mapping
  • Disulfide / Glycan analysis
  • Proteomics

 

Note: For custom package or special requirement, please contact our experts for details.

 

Build Your Early Developability Panel with Our Experts

 

 

Case Study #1: AC-SINS (Affinity-Capture Self-Interacting Nanoparticle Spectroscopy) Assesses Antibody Self-Association, Aggregation, and Viscosity

 

AC-SINS is a high-throughput assay used to evaluate antibody self-association and aggregation risks with low sample concentrations.

 

AC-SINS in vitro assay evaluates antibody self-association and aggregation risks using a high-throughput, low-sample workflow to support early risk assessment.

 

Figure 1: AC-SINS captures antibodies using coated gold nanoparticles to evaluate self-association and aggregation risk at low concentrations. The assay generates an AC-SINS score that helps differentiate well-behaved antibodies from self-associated candidates. Developability assessment data generated through our assay is typically consistent with published results for diverse antibodies to support early risk assessment during discovery.

 

 

Case Study #2: High-Throughput Baculovirus (BVP)/DNA/Insulin ELISA for Assessing Charge-Based and Non-Specific Binding Risks

 

BVP/DNA/Insulin ELISA is a high-throughput, cost-effective assay to evaluate non-specific, low-affinity, charge-based interactions of monoclonal antibodies. This assay provides a reliable indicator of poly-reactivity, generating actionable antibody developability data to prioritize candidates with more favorable profiles during discovery.

 

BVP/DNA/insulin ELISA for early-stage antibody developability assessment showing charge-absed and non-specific binding risks in early discovery.

 

Figure 2: In Panel A, mAb1 and mAb2 display concentration-dependent binding to BVP, DNA, and insulin, indicating high non-specific binding risks, while mAb3 shows minimal poly-reactivity. In Panel B, a panel of clinical monoclonal antibodies was assessed and normalized to a WuXi Biologics positive control, revealing diverse developability assessment profiles to support lead optimization.

 

Need Help Building Your Early Developability Panel?

 

 

Case Study #3: Forced Degradation Studies for Fit-for-Purpose Early Stability Assessment

 

Forced degradation studies evaluate antibody stability profiles under low-pH hold, freeze-thaw, and thermal stress (40 °C) conditions, using analytics such as iCIEF, SEC, CE-SDS, and LC-MS. This workflow supports early stability assessment using limited materials, enabling efficient candidate ranking and selection.

 

Stability testing using forced degradation studies showing low-pH hold, freeze-thaw, and thermal stress results measured by iCIEF, SEC, and CE-SDS.

 

Figure 3: Antibody samples were subjected to low-pH hold, freeze-thaw cycling, and thermal stress at 40 °C, with measurements collected at time zero (T0) and at the endpoint. iCIEF was used to monitor acidic, main, and basic charge variants, SEC assessed monomer purity and aggregation, and CE-SDS under non-reducing (NR) and reducing (R) conditions evaluated fragmentation. Bar charts illustrate changes in acidic species, main peak, and basic variants between T0 and endpoint, supporting developability assessment of therapeutic antibodies to guide engineering and optimization.

 

 

Case Study #4: Structure-Guided Engineering Reduces VHH Non-Specific Binding Risk

 

This case study highlights a structure-guided workflow to optimize a parental VHH with high non-specific binding risk. Early developability assessment identified high-risk BVP, DNA, and insulin ELISA signals. Structural modeling and hydrophobicity/aggregation analysis then guided high-risk site ranking and combinatorial mutation design, enabling selection of optimized variants with reduced ELISA scores and improved developability in early drug discovery.

 

Workflow figure showing structure-guided VHH optimization from parental antibody sequence through MicroDevelopability assessment, structural modeling, hydrophobicity and aggregation analysis, high-risk site ranking, and optimized variant selection, with BVP, DNA, insulin, DSF, and AC-SINS risk results plus ELISA score ranking of engineered variants.

 

Figure 4: Structure-guided VHH optimization workflow showing how early developability assessment, structural modeling, and high-risk site ranking guided combinatorial mutation design. Engineered variants were prioritized based on ELISA binding results, with a representative dataset shown, supporting selection of optimized VHH candidates with lower non-specific binding risk.

 

Start Your Early Developability Assessment

 

 

Case Study #5: Data-Driven Antibody Engineering Guided by Early-Stage Developability Assessment

 

With multiple successful projects, our team demonstrates extensive expertise in optimizing challenging antibody candidates. The examples below highlight how early antibody developability assessment and targeted optimization strategies enable improved molecular properties and smoother progression toward CMC readiness.

 

: Early-stage antibody developability assessment showing improved expression, reduced aggregation and non-specific binding, enhanced thermal stability, and extended PK-related performance.

 

Figure 5: Initial early-stage developability assessment identified downstream risks, such as low expression yield, degradation, non-specific binding, thermal instability, aggregation, and suboptimal PK-related characteristics. Guided by these insights, targeted antibody engineering was implemented to address them. Comparative results demonstrate improved expression yield, reduced degradation, elimination of non-specific binding, enhanced thermal stability, reduced aggregation, and extended PK-related performance. These data highlight the importance of early assessment to reduce downstream development risks and guide efficient lead optimization.

 

Frequently Asked Questions for our MicroDevelopability Services

Q: Should we run multiple developability assays or start with one key assay?

A: A staged funnel approach is often recommended. In early screening, high-throughput analysis focusing on in silico and PK-assessment can help rapidly filter large lead sets by addressing the most critical developability questions for each molecule type. For conventional mAbs, self-association, non-specific binding, and thermal stability may be prioritized. For bispecific antibodies, purity assessment may also be important. For ADCs, serum stability can be especially valuable.

After the number of leads is narrowed down, additional studies such as immunogenicity assessment or forced degradation can be added. If sequence analysis shows no high-risk hotspots, or if key PTM liabilities have already been removed during discovery, forced degradation for hotspot identification may not be necessary.

Q: How should immunogenicity assessment be designed?

A: Immunogenicity assessment should be selected based on the modality and mechanism of action of the molecule. Common approaches include evaluating T-cell proliferation and T-cell activation, but each assay has its own limitations. Therefore, fit-for-purpose assay selection is important for generating meaningful readouts.

Donor numbers are also critical. For early-stage screening, a smaller donor set may be used, while IND-enabling immunogenicity studies typically benefit from a larger donor panel, such as 30-50 donors when feasible.

Q: How should oxidation risk in the constant domain be addressed?

A: Oxidation risk should first be evaluated under chemical stress conditions to determine whether oxidation increases at the specific site of concern. If oxidation is elevated, the next step is to assess whether it affects potency, binding, or stability. If oxidation affects molecule function, early-stage protein engineering is recommended to reduce the liability while maintaining binding affinity and biological activity.

Q: What is the sample requirement for viscosity or concentrability testing?

A: Viscosity testing can be performed using microliter-scale measurements, with ~30 µL of material needed per test. Concentrability assessment also requires low sample consumption (~50 mg in total), considering potential protein loss during the concentration step.

Q: Can concentrability screening help address developability risks?

A: Concentrability screening can help identify the ability of a therapeutic protein to be concentrated to high spectral densities, typically above 100 mg/mL to 150 mg/mL, while remaining physically and chemically stable, soluble, and low in viscosity. Optimized buffer conditions may improve molecule behavior, such as reducing viscosity at high concentration.

Q: When should in vivo studies be considered instead of additional MicroDevelopability assays?

A: MicroDevelopability assays are useful for narrowing large lead sets before moving into more resource-intensive in vivo studies. When hundreds of molecules are being evaluated, it is not practical to advance all of them directly into animal studies. If a molecule shows a consistent risk signal in vitro, such as high non-specific binding scores, in vivo studies can be used for further verification to determine whether the liability translates into poor PK behavior.

Q: What type of antibody material is used for MicroDevelopability assessment: transiently expressed or stable cell line material?

A: Both transiently expressed and stable cell line-derived materials can be used, depending on the project stage and study objective. For early drug discovery and screening stages, transiently expressed material is more commonly used because it enables faster evaluation of multiple leads.

Q: After antibody optimization, can you assure customers that the antibody will retain its key features, such as affinity, target binding, and specificity?

A: Yes. Key biological functional properties such as affinity, target binding and specificity are important criteria for evaluating whether an optimization strategy is successful.

Q: If MicroDevelopability optimization may take 3-6 months, would in vivo studies be faster?

A: MicroDevelopability testing itself typically takes only one to two weeks. The full drug discovery and lead optimization process may take 3-6 months, depending on the number of leads and optimization cycles.

In vivo studies can provide direct PK behavior measurement, but they mainly indicate whether a potential PK issue exists. If so, additional lead optimization may still be needed. For projects with many leads, the MicroDevelopability panel is more cost-effective for early screening, optimization, and prioritization. For projects with only a small number of leads, in vivo studies may provide a more direct evaluation of PK behavior.

Q: Do you provide data from marketed mAbs so customers can compare their own mAb results? What about Fc-fusion proteins?

A: Marketed mAbs or customer-selected benchmark molecules can be included in the testing panel as reference analytes.

Q: Can MicroDevelopability tools be tailored for novel modalities?

A: A customized testing strategy can be developed based on the specific modality, molecule design, project stages, and key developability risks identified from in silico analysis.

Q: How should early-stage developability assessment be integrated into bispecific/TCE projects?

A: A staged workflow is recommended so that developability screening aligns with format-selection decisions. Start with light triage of the parental mAbs to remove obvious developability risks and reduce downstream pairing complexity. Then design and generate bispecific/TCE formats using a focused subset of qualified parental antibodies. After that, apply MicroDevelopability assessment to the bispecific antibodies, where format-specific liabilities can be more accurately evaluated and prioritized for optimization.

Q: Have you used any methods besides Mass Spec to analyze serum stability results?

A: In addition to LC-MS, Elisa and cell-based analysis can also be performed to evaluate serum stability.

Q: Can in vitro serum incubation predict in vivo stability?

A: In vitro serum incubation can indicate potential stability risks, but it does not fully correlate with in vivo stability. In vivo degradation involves both direct degradation and protein recycling pathways, which cannot be fully replicated in vitro. Using both assays enables comparative assessment, but in vivo studies are generally reserved for later development stages because of their high cost.

Q: Do study results using transiently produced mAbs closely align with those from stable cell lines?

A: For many early-stage assessments, such as AC-SINS, hydrophobicity, and charge distribution, the choice of cell line has limited impact, so transiently produced mAbs are suitable for evaluation. However, PTMs are highly dependent on the cell line and culture conditions, so final PTM assessments should be performed using stable cell lines. WuXi Biologics also uses the same parental CHO cell line for both transient and stable pool production to improve consistency in key attributes, especially glycosylation, and to increase the reliability of early-stage assessment.

Q: What does a change in iCIEF percentage indicate for the 40 °C sample?

A: A change in iCIEF percentage indicates changes in the distribution of main, acidic, and basic protein species. High-temperature stress can cause these shifts mainly through PTMs and chemical changes, such as deamidation and oxidation, that alter the charge properties of protein species.

More FAQs

Your Project. Our Expertise.

Contact Us